Selank

Overview

Selank is a synthetic 7-amino-acid peptide that produces anxiolytic and nootropic effects through the GABA system — but without the dependence, sedation, or memory impairment that come with benzodiazepines. That combination is what makes it interesting to researchers and clinicians alike.

It's derived from tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) with immunomodulatory properties. Selank's full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro — three additional amino acids added to extend its stability and biological activity.[3] Russian researchers at the Institute of Molecular Genetics developed it specifically to capture tuftsin's neuroimmune effects while adding anxiolytic and cognitive-enhancing properties.

In Russia, Selank is approved and used clinically as an anxiolytic. In the United States, it has no FDA approval and is classified as research-use only. That gap between its clinical use elsewhere and its regulatory status here is the central tension anyone researching this compound will run into.

Mechanism of Action

GABAergic modulation; BDNF regulation; neuropeptide gene expression

Selank's mechanism operates on two overlapping levels: direct modulation of GABA transmission and regulation of gene expression linked to neuropeptide signaling.[3]

The GABA system is the brain's primary inhibitory signaling network. When it's underactive, anxiety follows. Benzodiazepines force GABA-A receptors into a hyperactive state — effective, but blunt. Selank appears to modulate GABAergic tone more selectively, producing anxiolytic effects without the receptor downregulation that drives tolerance and dependence.[3]

The BDNF connection matters separately. BDNF is a protein that supports neuron survival, promotes synaptic plasticity, and plays a central role in learning and memory. Chronic stress and alcohol exposure both deplete BDNF in the hippocampus — which is one reason prolonged anxiety and alcohol use damage memory. Selank's ability to preserve hippocampal and prefrontal BDNF levels in alcohol-exposed rats[2] suggests a neuroprotective mechanism that operates independently of its acute anxiolytic effect.

Its origin as a tuftsin analog also gives it an immunomodulatory dimension. Tuftsin itself activates macrophages and natural killer cells and influences cytokine signaling. Selank retains some of this activity, which is why neuroimmune modulation appears among its documented effects — though the human relevance of this pathway remains less characterized than its CNS effects.[3]

The peptide's short 7-amino-acid structure (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is stable enough to reach target tissues but metabolizes relatively quickly, which may explain why its effects are described as anxiolytic without prolonged sedation.[3]

What the Evidence Shows

The honest summary: the evidence base for Selank is almost entirely preclinical. The published studies are consistent and mechanistically coherent, but they're rat studies. Extrapolating to humans requires caution.

Anxiety and withdrawal — morphine model: A 2022 study administered Selank at 0.3 mg/kg intraperitoneally to naloxone-precipitated morphine-dependent rats.[1] A single injection reduced the total morphine withdrawal index by 39.6%, significantly attenuated convulsive reactions and ptosis, and increased tactile sensitivity threshold 9-fold compared to active control. The effect was slightly inferior to diazepam at 2 mg/kg — but Selank produced these results without diazepam's sedative and dependence liabilities.

Memory protection — ethanol model: In rats given 10% ethanol as their only fluid source for 30 weeks, Selank at 0.3 mg/kg daily for 7 days prevented the formation of ethanol-induced memory and attention disturbances during withdrawal.[2] It also produced a cognitive-stimulating effect in unexposed animals. The mechanism appears to involve preservation of BDNF in the hippocampus and prefrontal cortex, both of which were depleted in ethanol-exposed controls.

Diazepam potentiation: Under unpredictable chronic mild stress conditions, Selank's anxiolytic effect was comparable to diazepam in the elevated plus maze test. Combined administration enhanced the effect of both compounds, suggesting a synergistic or additive interaction.[4] Even without chronic stress, Selank showed anxiolytic activity at standard doses.

Alcohol withdrawal anxiety: In alcohol-preferring rats (mean daily ethanol intake >5.0 g/kg), a single 0.3 mg/kg injection of Selank eliminated withdrawal-induced anxiety in elevated plus maze and social interaction tests, and prevented mechanical allodynia, without affecting ethanol consumption itself.[4][5]

Side Effects
Human side effect data for Selank is genuinely limited. What's known comes primarily from animal studies and practitioner-reported observations, not clinical trial adverse event reporting.

From practitioner and community reports (not clinical trial data):

The absence of serious adverse events in the published animal literature is notable, but it doesn't substitute for human safety data. If you're considering Selank under medical supervision, the honest answer is that the risk profile looks favorable in preclinical work, but the human safety database is thin. Work with a provider who will monitor you.